CIK细胞治疗恶性肿瘤的临床观察和护理

目的研究用脐血单个核细胞制备CIK细胞的抗肿瘤作用,探讨肿瘤生物治疗近期疗效的免疫指标及临床应用中的护理规范。方法分离脐血单个核细胞,用IL-2,CD3Ab和IFN-γ等细胞因子诱导CIK细胞;测定肿瘤患者用CIK细胞治疗前后外周血单核细胞(PBMC)的NK杀伤活性.静脉滴注过程中严密观察患者的体温和脉博等反应。结果肿瘤患者输注CIK细胞一疗程后,其PBMC的NK杀伤活性由62%升高到83%,平均升高29%,发热反应不到3%,大多在38℃以下,未经处理自行清退。结论(1)CIK细胞输注能明显提高肿瘤患者PBMC的NK活性。(2)CiK细胞输注临床应用安全有效,无明显副作用。(3)肿瘤病人PBMC的NK活性测定可望成为肿瘤生物治疗的一个近期疗效参数。

Clinical Observation and Nursing of CIK Cell Treating Patients with Malignant Tumor

Objective To study the anti-tumor effect of CIK cell prepared from umbilical blood,to explore the recent curative effect on tumor cases and seek better immune index for bio-therapy,and the nursing specification of CIK cell in clinical application.Methods IL-2,CD3Ab and IFN-γ was used to induce CIK cell from umbilical blood mononuclear cells(UBMC),the NK activity of peripheral blood mononuclear cells(PBMC) of 12 cases of malignant tumor patients were examined before and after CIK cell adopting immune therapy as well.The temperature and pulse were closely observed during the clinical application.Results The NK activity(killing K562 cell) of malignant tumor patient's PBMC had grown up to 83% from 62% by CIK cell transfusing,the even rising ratio is 29%.The fever cases is less than 3%,major was under 38℃,and was returned to normal in 2 h without special treatment.Conclusion(1) The NK activity of malignant tumor patient's PBMC can be obviously elevated by transfusing CIK cell.(2) CIK cell transfusion is a safe and curative method in clinical application.(3) The test of NK activity of PBMC of malignant tumor patient may become a recent objective immune index for tumor bio-therapy.